| Indicators | Browse All

Calidi Biotherapeutics, Inc. (CLDI)

Healthcare | Biotechnology | San Diego, United States | NYSE American
0.89 USD -0.06 (-6.306%) ⇩ (Oct. 13, 2026, 10:20 a.m. EDT)

Short-term:⯪☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 1:59 a.m. EDT

The immediate outlook is severely compromised by a pending 1-for-16 reverse stock split, which often signals distress or a desperate attempt to meet listing requirements rather than a strategic pivot. Fundamentally, the company is in a precarious state with negative earnings, massive cash burn, and a balance sheet that cannot sustain operations without further dilution or capital raises. The price action confirms this gravity, having erased nearly 99.87% of its value over the last three years with three consecutive years of declines. There is no dividend to provide income, and the statistical models suggest a continued downward drift in the near term. This is a high-risk speculative vehicle with no margin of safety.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.068625
AutoETS0.099336
AutoARIMA0.103500
MSTL0.108862

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 45%
H-stat 0.78
Ljung-Box p 0.000
Jarque-Bera p 0.362
Excess Kurtosis 0.15
Attribute Value
Sector Healthcare
Debt to Equity Ratio 61.985
Market Cap 3,272,061
Forward P/E -0.99
Beta 1.33
Website https://www.calidibio.com

Info Dump

Attribute Value
52 Week Change -0.9644461
Address1 4,475 Executive Drive
Address2 Suite 200
All Time High 26,476.8
All Time Low 0.937
Ask 0.8999
Ask Size 100
Average Daily Volume10 Day 37,960
Average Daily Volume3 Month 252,830
Average Volume 252,830
Average Volume10Days 37,960
Beta 1.329
Bid 0.87
Bid Size 500
Book Value 1.498
City San Diego
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.89
Current Ratio 1.677
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 0.9327
Day Low 0.87
Debt To Equity 61.985
Display Name Calidi Biotherapeutics
Dividend Yield 0.0
Ebitda -16,137,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.021
Enterprise Value 334,621
Eps Forward -0.9
Eps Trailing Twelve Months -36.47
Esg Populated 0
Exchange ASE
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 858 794 9605
Fifty Day Average 1.30354
Fifty Day Average Change -0.41354
Fifty Day Average Change Percent -0.3172438
Fifty Two Week Change Percent -96.44461
Fifty Two Week High 27.84
Fifty Two Week High Change -26.95
Fifty Two Week High Change Percent -0.96803164
Fifty Two Week Low 0.87
Fifty Two Week Low Change 0.01999998
Fifty Two Week Low Change Percent 0.022988483
Fifty Two Week Range 0.87 - 27.84
Financial Currency USD
First Trade Date Milliseconds 1,635,773,400,000
Float Shares 2,573,381
Forward Eps -0.9
Forward P E -0.9888889
Free Cashflow -10,016,875
Full Exchange Name NYSE American
Full Time Employees 29
Fullday Change -0.059899986
Fullday Change Percent -6.305926
Fullday Price 0.89
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.0061299996
Held Percent Institutions 0.01001
Implied Shares Outstanding 3,676,474
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,785,456,000
Last Split Factor 1:16
Long Business Summary Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Long Name Calidi Biotherapeutics, Inc.
Market us_market
Market Cap 3,272,061
Market State REGULAR
Max Age 86,400
Message Board Id finmb_572193913
Most Recent Quarter 1,782,777,600
Net Income To Common -23,455,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 2,816,760
Open 0.9327
Operating Cashflow -17,751,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 858 794 9600
Previous Close 0.9499
Price Hint 4
Price To Book 0.5941255
Profit Margins 0.0
Quick Ratio 1.34
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.059899986
Regular Market Change Percent -6.305926
Regular Market Day High 0.9327
Regular Market Day Low 0.87
Regular Market Day Range 0.87 - 0.9327
Regular Market Open 0.9327
Regular Market Previous Close 0.9499
Regular Market Price 0.89
Regular Market Time 1,791,901,219
Regular Market Volume 29,320
Return On Assets -1.34786
Return On Equity -6.72221
Sand P52 Week Change 0.17502642
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 3,676,474
Shares Percent Shares Out 0.0635
Shares Short 233,287
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 231,117
Short Name Calidi Biotherapeutics, Inc.
Short Percent Of Float 0.0638
Short Ratio 1.12
Source Interval 15
State CA
Symbol CLDI
Total Cash 4,071,000
Total Cash Per Share 1.57
Total Debt 1,942,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -36.47
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 5.691765
Two Hundred Day Average Change -4.801765
Two Hundred Day Average Change Percent -0.8436338
Type Disp Equity
Volume 29,320
Website https://www.calidibio.com
Zip 92,121